Interleukin-6 release and the acute-phase reaction in patients with acute myocardial infarction: a pilot study

J Lab Clin Med. 1992 May;119(5):574-9.

Abstract

We investigated the potential role of interleukin-6 as a mediator of the acute-phase reaction (APR) in patients with acute myocardial infarction. Of the six patients studied, five demonstrated increased plasma interleukin-6 levels. Interleukin-6 levels began to increase at 14 hours (mean; range = 8 to 20 hours) after the initial complaints and reached maximal levels of 28 to 250 U/mL (normal values less than 10 U/mL) after 36 hours (mean; range = 24 to 52 hours). No correlation was seen between the size of the interfaction as indicated by creatine kinase MB assays and the extent of the interleukin-6 increases (r = 0.44; p = 0.38). As an indicator of the APR, plasma C-reactive protein (CRP) levels were measured. CRP levels began to increase after 16 hours (mean; range = 8 to 24 hours) and reached maximum levels of 56 to 322 mg/L (normal values less than 3 mg/L) after 65 hours (mean; range = 48 to 92 hours). The increase of the interleukin-6 level preceded the increase of the CRP level in three patients and was simultaneous in two patients. Maximal interleukin-6 levels correlated significantly with maximal CRP levels (r = 0.96; p = 0.002). Thus these findings indicate that interleukin-6 is an important endogenous mediator for the APR in patients with acute myocardial infarction.

MeSH terms

  • Acute Disease
  • Acute-Phase Reaction*
  • C-Reactive Protein / metabolism
  • Creatine Kinase / metabolism
  • Humans
  • Interleukin-6 / physiology*
  • Myocardial Infarction / physiopathology*
  • Pilot Projects
  • Time Factors

Substances

  • Interleukin-6
  • C-Reactive Protein
  • Creatine Kinase